文献速递骨肿瘤小儿骨科

骨肉瘤与尤文肉瘤骨转移分期:三种影像学检查的比较

What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

该前瞻性诊断研究纳入54例经病理证实的骨肉瘤或尤文肉瘤患者,比较18F-FDG PET/CT、全身MRI和99mTc-MDP骨显像检测骨转移的灵敏度、特异度、PPV和NPV。结果显示三种检查在骨肉瘤和尤文肉瘤患者中的各项诊断性能指标置信区间均重叠,未发现差异。

要点

  • 骨肉瘤患者中18F-FDG PET/CT灵敏度100%、特异度100%,全身MRI灵敏度83%、特异度94%,骨显像灵敏度67%、特异度78%。
  • 尤文肉瘤患者中18F-FDG PET/CT与全身MRI灵敏度均为88%,骨显像为50%;三者特异度均≥95%。
  • 三种影像学检查诊断骨转移的灵敏度、特异度、PPV和NPV的95%CI均重叠,未显示差异。

核心结论

  • 在骨肉瘤和尤文肉瘤患者中,18F-FDG PET/CT、全身MRI和99mTc-MDP骨显像检测骨转移的灵敏度、特异度、PPV和NPV未见差异。

研究设计与样本

  • 前瞻性诊断研究,纳入2018年3月至2019年6月间54例经组织病理学证实的骨肉瘤或尤文肉瘤患者,年龄4至37岁。
  • 所有患者均接受99mTc-MDP骨显像、18F-FDG PET/CT和全身MRI进行初始骨转移分期,以多学科团队共识作为金标准。
  • 骨肉瘤组24例中6例有骨转移,尤文肉瘤组30例中8例有骨转移;中位随访17个月(范围12至27个月)。

主要发现

  • 骨肉瘤患者中,18F-FDG PET/CT、全身MRI和99mTc-MDP骨显像的灵敏度分别为100%(6/6,95%CI 54%–100%)、83%(5/6,95%CI 36%–100%)和67%(4/6,95%CI 22%–96%)。
  • 骨肉瘤患者中,上述三种检查的特异度分别为100%(18/18,95%CI 82%–100%)、94%(17/18,95%CI 73%–100%)和78%(14/18,95%CI 52%–94%)。
  • 尤文肉瘤患者中,18F-FDG PET/CT、全身MRI和99mTc-MDP骨显像的灵敏度分别为88%(7/8,95%CI 47%–100%)、88%(7/8,95%CI 47%–100%)和50%(4/8,95%CI 16%–84%)。
  • 尤文肉瘤患者中,上述三种检查的特异度分别为100%(22/22,95%CI 85%–100%)、95%(21/22,95%CI 77%–100%)和95%(21/22,95%CI 77%–100%)。
  • 所有诊断性能指标的95%置信区间均相互重叠,提示三种检查之间无差异。

关键数值与推荐

  • 骨肉瘤患者中,18F-FDG PET/CT的PPV为100%(6/6,95%CI 54%–100%)、NPV为100%(18/18,95%CI 82%–100%)。
  • 骨肉瘤患者中,全身MRI的PPV为83%(5/6,95%CI 36%–100%)、NPV为94%(17/18,95%CI 73%–100%)。
  • 骨肉瘤患者中,99mTc-MDP骨显像的PPV为50%(4/8,95%CI 16%–84%)、NPV为88%(14/16,95%CI 62%–98%)。
  • 尤文肉瘤患者中,18F-FDG PET/CT的PPV为100%(7/7,95%CI 59%–100%)、NPV为96%(22/23,95%CI 78%–100%)。
  • 尤文肉瘤患者中,全身MRI的PPV为88%(7/8,95%CI 50%–98%)、NPV为95%(21/22,95%CI 77%–99%);99mTc-MDP骨显像的PPV为80%(4/5,95%CI 28%–100%)、NPV为84%(21/25,95%CI 64%–96%)。

临床怎么用

  • 对于骨肉瘤和尤文肉瘤患者,三种影像学检查均可用于骨转移分期,临床选择可综合考虑可及性、辐射暴露和全身评估需求。
  • 为准确判断预后,仍需进行全面的转移灶评估,包括采用高灵敏度检查工具检测骨转移。
  • 鉴于本研究样本量小,尚不能据此做出广泛推荐,未来需更大规模研究加以验证。

局限性

  • 研究样本量较小(共54例),难以据此做出广泛推荐。
  • 7例患者在完成最低随访前死亡,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Skeletal metastases of bone sarcomas are indicators of poor prognosis. Various imaging modalities are available for their identification, which include bone scan, positron emission tomography/CT scan, MRI, and bone marrow aspiration/biopsy. However, there is considerable ambiguity regarding the best imaging modality to detect skeletal metastases. To date, we are not sure which of these investigations is best for screening of skeletal metastasis. QUESTION/PURPOSE: Which staging investigation-18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT), whole-body MRI, or 99mTc-MDP skeletal scintigraphy-is best in terms of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in detecting skeletal metastases in patients with osteosarcoma and those with Ewing sarcoma? METHODS: A prospective diagnostic study was performed among 54 of a total 66 consecutive osteosarcoma and Ewing sarcoma patients who presented between March 2018 and June 2019. The institutional review board approved the use of all three imaging modalities on each patient recruited for the study. Informed consent was obtained after thoroughly explaining the study to the patient or the patient's parent/guardian. The patients were aged between 4 and 37 years, and their diagnoses were proven by histopathology. All patients underwent 99mTc-MDP skeletal scintigraphy, 18F-FDG PET/CT, and whole-body MRI for the initial staging of skeletal metastases. The number and location of bone and bone marrow lesions diagnosed with each imaging modality were determined and compared with each other. Multidisciplinary team meetings were held to reach a consensus about the total number of metastases present in each patient, and this was considered the gold standard. The sensitivity, specificity, PPV, and NPV of each imaging modality, along with their 95% confidence intervals, were generated by the software Stata SE v 15.1. Six of 24 patients in the osteosarcoma group had skeletal metastases, as did 8 of 30 patients in the Ewing sarcoma group. The median (range) follow-up for the study was 17 months (12 to 27 months). Although seven patients died before completing the minimum follow-up, no patients who survived were lost to follow-up. RESULTS: With the number of patients available, we found no differences in terms of sensitivity, specificity, PPV, and NPV among the three staging investigations in patients with osteosarcoma and in patients with Ewing sarcoma. Sensitivities to detect bone metastases for 18F-FDG PET/CT, whole-body MRI, and 99mTc-MDP skeletal scintigraphy were 100% (6 of 6 [95% CI 54% to 100%]), 83% (5 of 6 [95% CI 36% to 100%]), and 67% (4 of 6 [95% CI 22% to 96%]) and specificities were 100% (18 of 18 [95% CI 82% to 100%]), 94% (17 of 18 [95% CI 73% to 100%]), and 78% (14 of 18 [95% CI 52% to 94%]), respectively, in patients with osteosarcoma. In patients with Ewing sarcoma, sensitivities to detect bone metastases for 18F-FDG PET/CT, whole-body MRI, and 99mTc-MDP skeletal scintigraphy were 88% (7 of 8 [95% CI 47% to 100%]), 88% (7 of 8 [95% CI 47% to 100%]), and 50% (4 of 8 [95% CI 16% to 84%]) and specificities were 100% (22 of 22 [95% CI 85% to 100%]), 95% (21 of 22 [95% CI 77% to 100%]), and 95% (21 of 22 [95% CI 77% to 100%]), respectively. Further, the PPVs for detecting bone metastases for 18F-FDG PET/CT, whole-body MRI, and 99mTc-MDP skeletal scintigraphy were 100% (6 of 6 [95% CI 54% to 100%]), 83% (5 of 6 [95% CI 36% to 100%]), and 50% (4 of 8 [95% CI 16% to 84%]) and the NPVs were 100% (18 of 18 [95% CI 82% to 100%]), 94% (17 of 18 [95% CI 73% to 100%]), and 88% (14 of 16 [95% CI 62% to 98%]), respectively, in patients with osteosarcoma. Similarly, the PPVs for detecting bone metastases for 18F-FDG PET/CT, whole-body MRI, and 99mTc-MDP skeletal scintigraphy were 100% (7 of 7 [95% CI 59% to 100%]), 88% (7 of 8 [95% CI 50% to 98%]), and 80% (4 of 5 [95% CI 28% to 100%]), and the NPVs were 96% (22 of 23 [95% CI 78% to 100%]), 95% (21 of 22 [95% CI 77% to 99%]), and 84% (21 of 25 [95% CI 64% to 96%]), respectively, in patients with Ewing sarcoma. The confidence intervals around these values overlapped with each other, thus indicating no difference between them. CONCLUSION: Based on these results, we could not demonstrate a difference in the sensitivity, specificity, PPV, and NPV between 18F-FDG PET/CT, whole-body MRI, and 99mTc-MDP skeletal scintigraphy for detecting skeletal metastases in patients with osteosarcoma and Ewing sarcoma. For proper prognostication, a thorough metastatic workup is essential, which should include a highly sensitive investigation tool to detect skeletal metastases. However, our study findings suggest that there is no difference between these three imaging tools. Since this is a small group of patients in whom it is difficult to make broad recommendations, these findings may be confirmed by larger studies in the future. LEVEL OF EVIDENCE: Level II, diagnostic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Aryal A, Kumar VS, Shamim SA, et al. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma? Clin Orthop Relat Res. 2021. PMID: 33635285. doi:10.1097/CORR.0000000000001681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。